Comparative Pharmacology
Head-to-head clinical analysis: EYLEA versus EYLEA HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EYLEA versus EYLEA HD.
EYLEA vs EYLEA HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF-A and VEGF-B) and placental growth factor (PlGF), thereby inhibiting angiogenesis and vascular permeability.
EYLEA HD (aflibercept) is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF-A) and placental growth factor (PlGF). It binds to VEGF-A and PlGF with high affinity, preventing their interaction with endothelial cell surface receptors VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and vascular permeability.
Intravitreal injection of 2 mg (0.05 mL) administered monthly (approximately every 4 weeks) for the first 3 months, followed by 2 mg every 8 weeks for neovascular age-related macular degeneration (nAMD). For diabetic macular edema (DME) and macular edema secondary to retinal vein occlusion (RVO), 2 mg monthly for 5 months, then 2 mg every 8 weeks. For diabetic retinopathy (DR) without DME, 2 mg every 8 weeks.
Intravitreal injection: 2 mg (0.04 mL of 50 mg/mL solution) every 4 weeks (monthly) for 3 initial doses, then 2 mg every 8 weeks (2 months) for neovascular (wet) age-related macular degeneration; 2 mg every 4 weeks for diabetic macular edema or macular edema secondary to retinal vein occlusion.
None Documented
None Documented
Intravitreal half-life: approximately 4.8 days in aqueous humor; systemic half-life: approximately 5–6 days after IVT injection due to slow absorption.
Approximately 11-13 days (range 7-19 days) in vitreous humor following intravitreal injection; terminal half-life in plasma is about 11-15 days. This supports monthly or bimonthly dosing intervals.
Primarily eliminated via the reticuloendothelial system; no renal or biliary excretion as intact aflibercept. Systemic clearance involves proteolytic catabolism.
Primarily metabolized via catabolic pathways; negligible renal elimination (<1% unchanged in urine). Biliary/fecal excretion of metabolites is minimal; systemic clearance is predominantly through proteolysis.
Category C
Category C
Anti-VEGF Agent
Anti-VEGF Agent